|
Market Cap (21-May) $2,216,115,200 (333rd) |
Close (30-Jun) $1.14 |
Volume (30-Jun) 2,606,681 |
Shortsold (5-May) 72,824,861 (5.70%) (40th) |
|
52w High $3.37 |
52w Low $0.88 |
P/E 454.55 |
EPS -0.14 |
MSB released this announcement to the ASX on 12 January 2022, 9:56. The announcement is not marked as price sensitive, and is 36 page(s) in length and 3.36MB in size.
You can view all announcements from MSB and see how they appear on a price chart on the announcements page.
At the date of this announcement, MSB was 9.471% short sold according to ASIC data. It was ranked the 5th most shorted stock on the ASX. It remains ranked 40th as of the latest reported data (05 May 2025).
| Other Recent Announcements from MSB | |
|---|---|
| Change of Director's Interest Notice | 13 June 2023, 8:56 |
| Mesoblast Director Appointed to Strategic Advisory Role | 5 June 2023, 9:41 |
| MSB Reports Q3 Financial Results and Operational Highlights | 26 May 2023, 8:32 |
| Biotech Showcase 2022 Presentation | 12 January 2022, 9:56 |
| Prospectus for Warrants Related to Oaktree Debt Refinance | 6 January 2022, 18:35 |
| Update on FDA Meeting for Remestemcel-L in Paediatric GvHD | 31 December 2021, 9:58 |
| FDAs OTAT Agrees to Primary Endpoint for Back Pain | 16 December 2021, 10:08 |
You must be logged in to post a reply.
Mesoblast 